logo
Plus   Neg
Share
Email

Merck: FDA Approves KEYTRUDA-Inlyta Combination - Quick Facts

Merck (MRK) announced the U.S. FDA has approved KEYTRUDA in combination with Inlyta for the first-line treatment of patients with advanced renal cell carcinoma. Inlyta (axitinib) is a tyrosine kinase inhibitor.

The approval was based on data from the pre-specified interim analysis of a phase 3 KEYNOTE-426 trial, where KEYTRUDA-axitinib combination reduced the risk of death by nearly half compared to Sunitinib. The KEYNOTE-426 trial also showed significant improvements in overall survival, progression-free survival and objective response rate for the KEYTRUDA-axitinib combination compared to sunitini.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The Federal Trade Commission (FTC) is in the process of sending out refund checks to consumers who were allegedly misled by Office Depot, Inc. and its software provider Support.com, Inc., into buying computer repair products and services. Out of $34 million, being the total amount of checks, Office Depot paid $25 million and Support.com paid $10 million as part of 2019 settlement. Gap Inc. partnered with fashion resale platform thredUP to facilitate the exchange of secondhand cloths. The retailer in a blog post said its customers can bring secondhand clothes in exchange for shopping credit that can be redeemed at Gap, Banana Republic, Athleta, or Janie and Jack. Customers who redeem their credits at Gap brands will receive an additional 15 percent payout bonus. Coca-Cola Co. (KO) on Friday reaffirmed its guidance for the full-year 2020 and provided an update on the expected impact from COVID-19 on first quarter 2020 results, ahead of its presentation at the Consumer Analyst Group of New York (CAGNY) Conference. For fiscal 2020, the company continues to project...
Follow RTT
>